Rennova Health Forms Advanced Molecular Services Group

Rennova Health (NASDAQ:RNVA, NASDAQ:RNVAZ) announced the formation of the Advanced Molecular Services Group set to focus on precision medicine, which will include CollabRX, Genomas, and Alethea Laboratories.
As quoted in the press release:

Rennova’s board of directors is considering all options to create shareholder value, and subject to required consents and approvals may spin off the Group to its stockholders.
AMS Group’s focus will be on mental and behavioral health, oncology, urology and cardiovascular disease. These areas benefit from understanding each person’s molecular profile and, in turn, determining the best treatment protocol. The Group’s proprietary technology combines Rennova’s advanced testing development whereby the results of laboratory data are interpreted to provide treatment guidance to physicians and patients, with expertise in machine learning. Over time the AMS Group is expected to expand its offerings in both areas to help deliver precision medicine-based solutions. Rennova has licensed a critical mobile application that brings these services to users and intends to release a beta version this summer. This would bring the AMS Group’s advanced products to patients, physicians and health organizations throughout the U.S. with testing to be conducted at Alethea Laboratories.
Rennova also announces that following an extensive search, Scott Jenkins, Ph.D., a long-time Silicon Valley Healthcare IT executive with nearly 30 years of experience, has been selected to lead the newly formed AMS Group as chief executive officer. Dr. Jenkins is responsible for the integration of the operations of the individual companies that comprise the Group.

Click here to read the full press release.

Source: www.marketwired.com